Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain

Conditions

• Chronic Low-back Pain
• Vertebrogenic Pain Syndrome

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Intracept™ Intraosseous Nerve Ablation — DEVICE
  Intracept™ Intraosseous Nerve Ablation for treatment of patients diagnosed with vertebrogenic pain

Study Details

Compile real-world outcomes of commercially approved Intracept™ Intraosseous Nerve Ablation Systems in the treatment of patients diagnosed with vertebrogenic pain.

Key Dates

Start date

Mar 26, 2025

Status verified

Jun 2026

Primary completion

Jul 31, 2034

Completion

Jul 31, 2034

Study Design

Enrollment

1,500 participants (estimated)

Arms

• Arm: Intracept™ Intraosseous Nerve Ablation Systems
  Subjects with pain treated with a commercially approved Intracept™ Intraosseous Nerve Ablation System

Primary Outcome Measure

Change in Disability (Oswestry Disability Index (ODI) from Baseline [ Time Frame: 60-months post-procedure ]

Central Contacts

• Ann Yamano
  855-213-9890
  [email protected]
• Diane Keesey
  855-213-9890
  [email protected]

Locations (17)

Find similar trials in Flagstaff, AZ

Related Studies

• DBS of the SCC for the Treatment of Medically Refractory CLBP
  Recruiting · University of California, Los Angeles · Los Angeles, California
• Brain Imaging Biomarkers for Response to Spinal Cord Stimulation in Patients With Chronic Low Back Pain
  Recruiting · University of California, Los Angeles · Los Angeles, California
• Transcutaneous Spinal Cord Stimulation for Chronic Low Back Pain
  Recruiting · University of California, San Francisco · San Francisco, California
• Transcutaneous Electrical Nerve Stimulation (TENS) and Low Back Pain
  Recruiting · University of Hartford · West Hartford, Connecticut